Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | June 18, 2026 | June 23, 2026 |
| CELGENE CORP /DE/CELG · Entity 15781 | Director · see remarks | February 14, 2017 | February 16, 2017 |
| DICK'S SPORTING GOODS, INC.DKS · Entity 556 | Director | March 22, 2020 | March 24, 2020 |
| INCYTE CORPINCY · Entity 3182 | Director | June 08, 2026 | June 10, 2026 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 154,156 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 2,816 · Balance 154,156 |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Exercise / conversion · Disposed 2,816 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 2,927 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 2,927 · Balance 2,927 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.16 · Expires 2036-06-18 | Direct | 14,950 |
Reported balance
After 2026-06-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-18 · Grant · Acquired 14,950 · Balance 14,950 F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.
CELGENE CORP /DE/
Report date February 14, 2017 · Filed February 16, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 16,322 |
Reported balance
After 2017-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-14 · Grant · Acquired 16,322 · Balance 16,322 F1: Each share of phantom stock represents a right to receive one share of common stock. F3: The reporting person was awarded 16,322 shares of common stock pursuant to the 2014-2016 Long Term Incentive Plan under the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015). The reporting person deferred the receipt of such 16,322 shares of common stock and received instead 16,322 shares of phantom stock pursuant to the Celgene Corporation 2005 Deferred Compensation Plan. F2: The phantom stock becomes payable six months following the reporting person's termination of employment with Celgene Corporation. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of phantom stock represents a right to receive one share of common stock.
F2: The phantom stock becomes payable six months following the reporting person's termination of employment with Celgene Corporation.
F3: The reporting person was awarded 16,322 shares of common stock pursuant to the 2014-2016 Long Term Incentive Plan under the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 15, 2015). The reporting person deferred the receipt of such 16,322 shares of common stock and received instead 16,322 shares of phantom stock pursuant to the Celgene Corporation 2005 Deferred Compensation Plan.
DICK'S SPORTING GOODS, INC.
Report date March 22, 2020 · Filed March 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 55,288 |
Reported balance
After 2020-03-22 transaction · row 1
1 source rowRow 1 · 2020-03-22 · Grant · Acquired 9,518 · Balance 55,288 F1: Shares of time-based restricted stock, subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of time-based restricted stock, subject to vesting.
INCYTE CORP
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,968 |
Reported balance
After 2026-06-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 1,642 · Balance 20,968 F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
| Non Qualfied Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.64 · Expires 2036-06-07 | Direct | 6,111 |
Reported balance
After 2026-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-08 · Grant · Acquired 6,111 · Balance 6,111 F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). |
Filing footnotes · ownership attribution and instrument terms
F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).
MADRIGAL PHARMACEUTICALS, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,551 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 454 · Balance 1,551 F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $499.86 · Expires 2036-06-17 | Direct | 766 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 766 · Balance 766 F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2022 Filed Oct 4, 2022 20:01 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 291 | $66.64 | $19,392.24 |
DisclosureSEC source: 0001209191-22-052164 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,221 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:01 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 275 | $75.97 | $20,891.75 |
DisclosureSEC source: 0001209191-22-040182 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,930 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 2,144 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:01 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,124 | $0.00 Strike: $68.55 | $0.00 |
DisclosureSEC source: 0001209191-22-037800 · doc4.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,124 Underlying: Common Stock · 9,124 shares Expires 2032-06-14 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:01 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,144 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037800 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,655 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 20:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 47,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000032 · wf-form4_164979367185851.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,800 Underlying: Common stock · 47,800 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on April 8, 2022. Beginning on April 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on April 8, 2022. Beginning on April 8, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 20:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 170,000 | $0.00 Strike: $29.46 | $0.00 |
DisclosureSEC source: 0001439222-22-000032 · wf-form4_164979367185851.xml · derivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common stock · 170,000 shares Expires 2032-04-08 F1 · derivative.exercise_date: This option was granted on April 8, 2022. The shares underlying this option vest as to 25% of the underlying shares on April 8, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 280 | $79.42 | $22,237.60 |
DisclosureSEC source: 0001209191-22-022293 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,511 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 3,674 | $29.08 | $106,839.92 |
DisclosureSEC source: 0001439222-22-000017 · wf-form4_164565061538990.xml · nonDerivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,897 Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 12,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000017 · wf-form4_164565061538990.xml · derivative · entry 3 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,380 Underlying: Common stock · 12,379 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 12,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000017 · wf-form4_164565061538990.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 11,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000012 · wf-form4_164504888183057.xml · derivative · entry 3 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,333 Underlying: Common stock · 11,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 3,505 | $30.50 | $106,902.50 |
DisclosureSEC source: 0001439222-22-000012 · wf-form4_164504888183057.xml · nonDerivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,192 Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 22:01 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 11,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000012 · wf-form4_164504888183057.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:16 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 289 | $73.40 | $21,212.60 |
DisclosureSEC source: 0001209191-22-000702 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,231 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:32 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 271 | $68.78 | $18,639.38 |
DisclosureSEC source: 0001209191-21-058982 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,942 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 11:19 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 238 | $84.13 | $20,022.94 |
DisclosureSEC source: 0001209191-21-044644 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,671 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,923 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| May 26, 2021 Filed May 28, 2021 11:10 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,010 | $0.00 Strike: $83.16 | $0.00 |
DisclosureSEC source: 0001209191-21-036405 · doc4.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,010 Underlying: Common Stock · 8,010 shares Expires 2031-05-25 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| May 26, 2021 Filed May 28, 2021 11:10 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036405 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,433 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 21:53 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 251 | $81.27 | $20,398.77 |
DisclosureSEC source: 0001209191-21-024210 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,510 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 14, 2021 Filed Feb 17, 2021 21:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 11,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000011 · wf-form4_161359639686404.xml · derivative · entry 3 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,667 Underlying: Common stock · 11,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 14, 2021 Filed Feb 17, 2021 21:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 3,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000011 · wf-form4_161359639686404.xml · nonDerivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,363 Read SEC document |
| February 14, 2021 Filed Feb 17, 2021 21:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 11,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000011 · wf-form4_161359639686404.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 163,000 | $0.00 Strike: $56.68 | $0.00 |
DisclosureSEC source: 0001439222-21-000007 · wf-form4_161316500956020.xml · derivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,000 Underlying: Common stock · 163,000 shares Expires 2031-02-10 F1 · derivative.exercise_date: This option was granted on February 10, 2021. The shares underlying this option vest as to 25% of the underlying shares on February 10, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:51 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 237 | $86.98 | $20,614.26 |
DisclosureSEC source: 0001209191-21-001217 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,259 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 20:48 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 219 | $89.74 | $19,653.06 |
DisclosureSEC source: 0001209191-20-052637 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,022 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 22:02 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 202 | $103.97 | $21,001.94 |
DisclosureSEC source: 0001209191-20-039885 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,803 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,282 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:18 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,514 | $0.00 Strike: $98.68 | $0.00 |
DisclosureSEC source: 0001209191-20-032592 · doc4.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,514 Underlying: Common Stock · 10,514 shares Expires 2030-05-25 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:18 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032592 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,601 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 20:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 3,673 | $40.64 | $149,270.72 |
DisclosureSEC source: 0001439222-20-000030 · wf-form4_158698236240236.xml · nonDerivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,428 Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 12,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000030 · wf-form4_158698236240236.xml · derivative · entry 3 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,759 Underlying: Common stock · 12,379 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified commercial milestone was determined to have been met on April 13, 2020, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified commercial milestone was determined to have been met on April 13, 2020, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:26 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 12,379 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000030 · wf-form4_158698236240236.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 21:18 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 270 | $73.23 | $19,772.10 |
DisclosureSEC source: 0001209191-20-022695 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,319 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| March 22, 2020 Filed Mar 24, 2020 20:32 UTC | DICK'S SPORTING GOODS, INC. DKS · Entity 556 | GrantCommon Stock, par value $0.01 per share | 9,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001089063-20-000035 · wf-form4_158508196150334.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,288 F1 · shares: Shares of time-based restricted stock, subject to vesting. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:52 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 34,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000017 · wf-form4_158214915116382.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common stock · 34,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:52 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 137,000 | $0.00 Strike: $51.51 | $0.00 |
DisclosureSEC source: 0001439222-20-000017 · wf-form4_158214915116382.xml · derivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,000 Underlying: Common stock · 137,000 shares Expires 2030-02-14 F1 · derivative.exercise_date: This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:15 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 218 | $87.32 | $19,035.76 |
DisclosureSEC source: 0001209191-20-000886 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,049 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | PurchaseCommon stock | 40,322 | $31.00 | $1,249,982.00 |
DisclosureSEC source: 0001439222-19-000025 · wf-form4_157385189418467.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,722 F1 · price: All shares were purchased at $31.00 per share in an underwritten public offering that closed on November 13, 2019. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 20:14 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 251 | $74.23 | $18,631.73 |
DisclosureSEC source: 0001209191-19-051647 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,831 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:39 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 203 | $84.96 | $17,246.88 |
DisclosureSEC source: 0001209191-19-040335 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,580 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. F2 · balance_after: Includes an aggregate of 1,520 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| May 31, 2019 Filed May 31, 2019 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033620 · doc4.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| May 31, 2019 Filed May 31, 2019 20:05 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-033620 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 21:11 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 12,472 | $0.00 Strike: $75.03 | $0.00 |
DisclosureSEC source: 0001209191-19-026439 · doc4.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,472 Underlying: Common Stock · 12,472 shares Expires 2029-04-25 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 21:11 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 1,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-026439 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,377 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 18:56 UTC | DICK'S SPORTING GOODS, INC. DKS · Entity 556 | GrantCommon Stock, par value $0.01 per share | 4,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001089063-19-000020 · wf-form4_155449054641329.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,770 F1 · shares: Shares of time-based restricted stock, subject to vesting. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 20:47 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 145 | $86.01 | $12,471.45 |
DisclosureSEC source: 0001209191-19-022599 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 857 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:28 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantPerformance share units · Derivative | 42,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-007343 · doc4.xml · derivative · entry 2 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,695 Underlying: Common stock · 42,695 shares Expires 2024-02-01 F2 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The performance share units vest if, during the five-year period beginning on February 1, 2019 and ending on February 1, 2024, the closing price of the issuer's common stock equals or exceeds $120 per share for at least 20 consecutive trading days at any time during such five-year period. F3 · derivative.expiration_date: The performance share units vest if, during the five-year period beginning on February 1, 2019 and ending on February 1, 2024, the closing price of the issuer's common stock equals or exceeds $120 per share for at least 20 consecutive trading days at any time during such five-year period. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:28 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 350,346 | $0.00 Strike: $53.87 | $0.00 |
DisclosureSEC source: 0001209191-19-007343 · doc4.xml · derivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,346 Underlying: Common stock · 350,346 shares Expires 2029-01-31 F1 · derivative.exercise_date: This option was granted on February 1, 2019. The shares underlying this option vest as to 25% of the shares on February 1, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:12 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 196 | $63.59 | $12,463.64 |
DisclosureSEC source: 0001209191-19-000904 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 712 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 20:19 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 180 | $69.08 | $12,434.40 |
DisclosureSEC source: 0001209191-18-053114 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 20:02 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 186 | $67.00 | $12,462.00 |
DisclosureSEC source: 0001209191-18-040920 · doc4.xml · nonDerivative · entry 1 FOUSE JACQUALYN A · CIK 0001405288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336 F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.